News & AnalysisVentus Therapeutics rallies $140m Series CVentus Therapeutics, Inc., a biopharmaceutical company, has raised $140 million in Series C financing.ByIris Dorbian9 February 2022•1 min readJavaScript is required to read this article. Please enable it in your browser and reload the page.DealsHealthcareBriefs